Bertrand Blankert

Prof. Bertrand Blankert

University of Mons | Pharmaceutical Analysis Lab.
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2015 in Biomacromolecules
Verified
Journal Article
Closed access
ANAmandine Nachtergael
Amandine Nachtergael
OCOlivier Coulembier
Olivier Coulembier
Philippe DuboisPhilippe Dubois
Philippe Dubois
MHMaxime Helvenstein
Maxime Helvenstein
PDPierre Duez
Pierre Duez
LMLaetitia Mespouille
Laetitia Mespouille

1 January 2015 in Journal of Analytical Methods in Chemistry
Verified
Journal Article
Open access
PDF file
MFMarwa Ahmed Fouad
Marwa Ahmed Fouad
MHMaxime Helvenstein
Maxime Helvenstein
BBBertrand Blankert
Bertrand Blankert
Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL/min using gradient elution mode. AµSPE (solid phase extraction) procedure, using Oasis MCXµElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (β= 95% and acceptance limits = ±15%) over the ranges 5–250 ng/mL for afatinib and from 5 to 400 ng/mL for ibrutinib in human plasma.

28 July 2021 in Malaria Journal
Verified
Journal Article
Open access
PDF file
Médéric LoyezMédéric Loyez
Médéric Loyez
MWMathilde Wells
Mathilde Wells
SHStéphanie Hambÿe
Stéphanie Hambÿe
FHFrançois Hubinon
François Hubinon
BBBertrand Blankert
Bertrand Blankert
Christophe CaucheteurChristophe Caucheteur
Christophe Caucheteur
Background: Early malaria diagnosis and its profiling require the development of new sensing platforms enabling rapid and early analysis of parasites in blood or saliva, aside the widespread rapid diagnostic tests (RDTs). Methods: This study shows the performance of a cost-effective optical fiber-based solution to target the presence of Plasmodium falciparum histidine-rich protein 2 (PfHRP2). Unclad multimode optical fiber probes are coated with a thin gold film to excite Surface Plasmon Resonance (SPR) yielding high sensitivity to bio-interactions between targets and bioreceptors grafted on the metal surface. Results: Their performances are presented in laboratory conditions using PBS spiked with growing concentrations of purified target proteins and within in vitro cultures. Two probe configurations are studied through label-free detection and amplification using secondary antibodies to show the possibility to lower the intrisic limit of detection. Conclusions: As malaria hits millions of people worldwide, the improvement and multiplexing of this optical fiber technique can be of great interest, especially for a future purpose of using multiple receptors on the fiber surface or several coated-nanoparticles as amplifiers.

8 May 2018 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
INIoan O. Neaga
Ioan O. Neaga
SHStephanie Hambye
Stephanie Hambye
EBEde Bodoki
Ede Bodoki
CPClaudio Palmieri
Claudio Palmieri
EAEugénie Ansseau
Eugénie Ansseau
BBBertrand Blankert
Bertrand Blankert

1 June 2013 in Clinica Chimica Acta
Verified
Journal Article
Closed access
CLC. Lenaerts
C. Lenaerts
MDM. Demeyer
M. Demeyer
PGP. Gerbaux
P. Gerbaux
BBBertrand Blankert
Bertrand Blankert

10 August 2020 in Biology
Verified
Journal Article
Open access
PDF file
LSLaura Soumoy
Laura Soumoy
MWMathilde Wells
Mathilde Wells
Ahmad NajemAhmad Najem
Ahmad Najem
MKMohammad Krayem
Mohammad Krayem
GGGhanem E. Ghanem
Ghanem E. Ghanem
FJFabrice Journe
Fabrice Journe
Melanoma is the most common cancer in young adults, with a constantly increasing incidence. Metastatic melanoma is a very aggressive cancer with a 5-year survival rate of about 22−25%. This is, in most cases, due to a lack of therapies which are effective on the long term. Hence, it is crucial to find new therapeutic agents to increase patient survival. Toad venoms are a rich source of potentially pharmaceutically active compounds and studies have highlighted their possible effect on cancer cells. We focused on the venoms of two different toad species: Bufo bufo and Rhinella marina. We screened the venom crude extracts, the fractions from crude extracts and isolated biomolecules by studying their antiproliferative properties on melanoma cells aiming to determine the compound or the combination of compounds with the highest antiproliferative effect. Our results indicated strong antiproliferative capacities of toad venoms on melanoma cells. We found that these effects were mainly due to bufadienolides that are cardiotonic steroids potentially acting on the Na+/K+ ATPase pump which is overexpressed in melanoma. Finally, our results indicated that bufalin alone was the most interesting compound among the isolated bufadienolides because it had the highest antiproliferative activity on melanoma cells.